Anavex Life Sciences Corp. (NASDAQ:AVXL) Short Interest Update

Anavex Life Sciences Corp. (NASDAQ:AVXL) was the target of a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 17,830,000 shares, a decline of 14.9% from the June 15th total of 20,940,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 15.4 days.

Institutional Trading of Anavex Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in shares of Anavex Life Sciences during the 2nd quarter valued at about $57,000. Fiduciary Alliance LLC purchased a new position in shares of Anavex Life Sciences during the first quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Anavex Life Sciences by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,773 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,275 shares during the last quarter. Belpointe Asset Management LLC bought a new position in shares of Anavex Life Sciences during the 4th quarter valued at $93,000. Finally, Hayek Kallen Investment Management purchased a new position in Anavex Life Sciences in the 4th quarter worth $99,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, June 11th.

Anavex Life Sciences Trading Up 8.0 %

Shares of AVXL traded up $0.43 during midday trading on Monday, hitting $5.82. 848,513 shares of the company traded hands, compared to its average volume of 1,307,664. Anavex Life Sciences has a one year low of $3.25 and a one year high of $10.45. The stock has a 50-day moving average of $4.13 and a 200-day moving average of $4.90.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, equities analysts forecast that Anavex Life Sciences will post -0.55 EPS for the current fiscal year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.